Literature DB >> 6199207

Stability of 111In-bleomycin in vivo--properties compared with 57Co-bleomycin.

D Y Hou, H Hoch, G S Johnston, K C Tsou, R J Farkas, E E Miller.   

Abstract

111Indium-bleomycin (111In-BLM) and 57Co-bleomycin (57Co-BLM) were prepared and their distributions were compared in the tissues, blood, and urine in tumor-bearing and in untreated mice and rats. Autoradiographs of electrophoresis gels showed that patterns for urine from untreated and tumor-bearing animals, collected 1-3 h or 48 h after injection of 111In-BLM were similar to those for in vitro mixtures of urine and 111In-BLM, but differed from the patterns obtained with 111InCl3 under in vivo or in vitro conditions. In rats bearing mammary adenocarcinoma, 48 h after administration of the radiopharmaceutical, the activity ratio of tumor to eleven different tissues was 1.2-4.6 times higher for injected 111In-BLM than for 111InCl3 (P less than or equal to 0.001 or P less than or equal to 0.05). Imaging with a gamma camera depicted tumors in mice more distinctly with 111In-BLM than with 111InCl3. These findings were interpreted as reflecting the stability of 111In-BLM in vivo. The tumor concentration (%dose/g) was higher for the viable area than for the necrotic area for 111In-BLM, but the reverse was true for 57Co-BLM.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6199207     DOI: 10.1007/bf00251616

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  15 in total

1.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

2.  Distribution of labeled bleomycin in normal and tumor-bearing mice.

Authors:  R B Grove; W C Eckelman; R C Reba
Journal:  J Nucl Med       Date:  1973-12       Impact factor: 10.057

Review 3.  Neoplasm localization with radionuclides.

Authors:  V Lopez-Majano; J Alvarez-Cervera
Journal:  Eur J Nucl Med       Date:  1979-10

4.  Purification of bleomycins.

Authors:  H Umezawa; Y Suhara; T Takita; K Maeda
Journal:  J Antibiot (Tokyo)       Date:  1966-09       Impact factor: 2.649

5.  Cobalt-labeled bleomycin--a new radiopharmaceutical for tumor localization. A comparative clinical evaluation with gallium citrate.

Authors:  K P Poulose; A E Watkins; R C Reba; W C Eckelman; M Goodyear
Journal:  J Nucl Med       Date:  1975-09       Impact factor: 10.057

6.  Chemical and biologic properties of isolated radiolabeled bleomycin preparations.

Authors:  W C Eckelman; W J Rzeszotarski; B A Siegel; H Kubota; M Chelliah; J Stevenson; R C Rebra
Journal:  J Nucl Med       Date:  1975-11       Impact factor: 10.057

7.  Clinical evaluation of radiolabeled bleomycin (BLEO) for tumor detection.

Authors:  R B Grove; R C Reba; W C Eckelman; M Goodyear
Journal:  J Nucl Med       Date:  1974-06       Impact factor: 10.057

8.  Chemical properties and tumor affinity of separated isomers of cobalt-bleomycin.

Authors:  J Kakinuma; R Kagiyama; H Orii
Journal:  Eur J Nucl Med       Date:  1980-04

9.  Diagnostic value of female genital malignant tumors by using 111In-bleomycin scintigraphy.

Authors:  T Kida; M Ikeda; M Saito
Journal:  Radioisotopes       Date:  1978-09

10.  Clinical evaluation of radio-labelled bleomycin for tumor detection.

Authors:  J J Rasker; H Beekhuis; M A van de Poll; A Versluis; H Jurjens; M G Woldring
Journal:  Nuklearmedizin       Date:  1978-12       Impact factor: 1.379

View more
  2 in total

1.  Positive 57Co-bleomycin scintigraphy in silent mediastinal metastases of malignant melanoma.

Authors:  R A Valdés Olmos; J H van der Bergh; J F den Hamer; H J Serdijn
Journal:  Eur J Nucl Med       Date:  1985

2.  Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.

Authors:  Bart Cornelissen; Veerle Kersemans; Sonali Darbar; James Thompson; Ketan Shah; Kate Sleeth; Mark A Hill; Katherine A Vallis
Journal:  Cancer Res       Date:  2011-05-17       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.